Infectious Disease Therapeutics Market Analysis By Disease Type (HIV infection, Influenza, Malaria, Tuberculosis, Hepatitis, and HPV infection), By Region, And Segment Forecasts, 2014 - 2025

Published: Aug, 2017 | Pages: 81 | Publisher: Grand View Research
Industry: Medical Devices | Report Format: Electronic (PDF)

The global top 6 infectious disease therapeutics market is expected to reach USD 86.2 billion by 2025, according to a new report by Grand View Research, Inc. The market is primarily driven by increasing number of Human Immunodeficiency Virus (HIV), Human Papillomavirus (HPV), TB, and hepatitis cases globally.

Government and private organizations are investing heavily in the healthcare sector to prevent, diagnose, and treat infectious diseases; rising investments for development of new drugs to treat infectious diseases, and increasing number of initiatives for creating awareness about these conditions are expected to boost the market during the forecast period. Furthermore, increasing number of patent expirations and entry of generic drugs in the market are expected to increase the demand for infectious disease therapeutics due to their low prices.

In addition, availability of reimbursement for diagnosis & treatment of these infections and free distribution of drugs by manufacturers in regions with high incidence of these diseases are factors further expected to propel the market growth. However, low penetration rate of anti-infective and availability of large number of counterfeit drugs are expected to restraint the market growth during the forecast period.

North American market held the largest share in 2016. Presence of large number of manufacturers, favorable reimbursement scenario, and increasing healthcare expenditure are major factors responsible for the largest share held by this region. However, Asia Pacific is likely to grow at the highest rate between 2017 and 2025. High prevalence of infectious diseases; improving economic conditions in Asian countries, rising government initiatives to increase the adoption of treatments for infectious diseases, and rising funding activities are factors that can be attributed for the highest growth rate of this region during the forecast period.

Further key findings from the report suggest :

• The HIV therapeutics segment held the largest revenue share in 2016 due to high number of HIV cases globally

• North America dominated the global market owing to the strong reimbursement framework coupled with high adoption rate of treatments for infectious diseases

• The HPV therapeutics segment is estimated to grow at the highest rate during the forecast period

• Some of the key players areNovartis AG, Gilead, GlaxoSmithKline plc, Janssen Pharmaceutical, Inc., F. Hoffmann-La Roche Ltd., BioCryst Pharmaceuticals, Inc., and Boehringer Ingelheim GmbH

 Table of Contents

Chapter 1 Research Methodology
                 1.1 Information Procurement
                 1.2 Data Analysis
Chapter 2 Executive Summary
                 2.1 Market Snapshot
Chapter 3 Infectious Disease Therapeutics Market Variables, Trends & Scope
                 3.1 Market Segmentation & Scope
                 3.2 Market Driver Analysis
                     3.2.1 Rising funding activities by various organizations
                     3.2.2 Increasing prevalence of infectious diseases
                     3.2.3 Growing awareness activities by non-profit organizations
                     3.2.4 Patent expiration of branded drugs is expected to increase the availability of drugs
                 3.3 Market Restraint Analysis
                     3.3.1 Lack of reimbursement in selected countries
                     3.3.2 Low penetration rates of diagnosis and treatment
                 3.4 Penetration & Growth Prospect Mapping
                 3.5 Top 6 infectious disease therapeutics Market - SWOT Analysis, by Factor (Political & legal, Economic and Technological)
                 3.6 Industry Analysis - Porter's
Chapter 4 Infectious Disease Therapeutics Market: Disease Type Estimates & Trend Analysis
                 4.1 Top Six Infectious Disease Therapeutics Market: Disease Type Movement Analysis
                 4.2 HIV
                     4.2.1 HIV market estimates and forecasts, 2014 - 2025 (USD Million) 
                     4.2.2 HIV market estimates and forecasts, by drug type 2014 - 2025 (USD Million) 
                 4.3 Influenza
                     4.3.1 Influenza market estimates and forecasts, 2014 - 2025 (USD Million) 
                     4.3.2 Influenza market estimates and forecasts, by drug type 2014 - 2025 (USD Million) 
                 4.4 Hepatitis
                     4.4.1 Hepatitis market estimates and forecasts, 2014 - 2025 (USD Million) 
                 4.5 Tuberculosis
                     4.5.1 TB market estimates and forecasts, 2014 - 2025 (USD Million) 
                     4.5.2 TB market estimates and forecasts, by drug type 2014 - 2025 (USD Million) 
                 4.6 Malaria
                     4.6.1 Malaria market estimates and forecasts, 2014 - 2025 (USD Million) 
                     4.6.2 Malaria market estimates and forecasts, by drug type 2014 - 2025 (USD Million) 
                 4.7 HPV
                     4.7.1 HPV market estimates and forecasts, 2014 - 2025 (USD Million) 
Chapter 5 Infectious Disease Therapeutics Market: Regional Estimates & Trend Analysis, and By Product
                 5.1 Top Six Infectious Disease Therapeutics Market: Regional Movement Analysis
                 5.2 North America
                     5.2.1 Market estimates & forecasts, 2014 - 2025 (USD Million)
                     5.2.2 U.S.
                         5.2.2.1 Market, by disease type estimates & forecasts, 2014 - 2025 (USD Million)
                     5.2.3 Canada
                         5.2.3.1 Market, by disease type estimates & forecasts, 2014 - 2025 (USD Million)
                 5.3 Europe
                     5.3.1 Market estimates & forecasts, 2014 - 2025 (USD Million)
                     5.3.2 UK
                         5.3.2.1 Market, by disease type estimates & forecasts, 2014 - 2025 (USD Million)
                     5.3.3 Germany
                         5.3.3.1 Market, by disease type estimates & forecasts, 2014 - 2025 (USD Million)
                 5.4 Asia Pacific
                     5.4.1 Market estimates & forecasts, 2014 - 2025 (USD Million)
                     5.4.2 Japan
                         5.4.2.1 Market, by disease type estimates & forecasts, 2014 - 2025 (USD Million)
                     5.4.3 China
                         5.4.3.1 Market, by disease type estimates & forecasts, 2014 - 2025 (USD Million)
                 5.5 Latin America
                     5.5.1 Market estimates & forecasts, 2014 - 2025 (USD Million)
                     5.5.2 Brazil
                         5.5.2.1 Market, by disease type estimates & forecasts, 2014 - 2025 (USD Million)
                     5.5.3 Mexico
                         5.5.3.1 Market, by disease type estimates & forecasts, 2014 - 2025 (USD Million)
                 5.6 Middle East and Africa (MEA)
                     5.6.1 Market estimates & forecasts, 2014 - 2025 (USD Million)
                     5.6.2 South Africa
                         5.6.2.1 Market, by disease type estimates & forecasts, 2014 - 2025 (USD Million)
Chapter 6 Competitive Landscape
                 6.1 Company Profiles
                     6.1.1 Gilead Sciences, Inc.
                         6.1.1.1 Company overview
                         6.1.1.2 Financial performance
                         6.1.1.3 Product benchmarking
                         6.1.1.4 Strategic initiatives
                     6.1.2 GlaxoSmithKline plc
                         6.1.2.1 Company overview
                         6.1.2.2 Financial performance
                         6.1.2.3 Product benchmarking
                     6.1.3 Janssen Pharmaceutical
                         6.1.3.1 Company overview
                         6.1.3.2 Financial performance
                         6.1.3.3 Product benchmarking
                         6.1.3.4 Strategic initiatives
                     6.1.4 F. Hoffmann-La Roche AG
                         6.1.4.1 Company overview
                         6.1.4.2 Financial performance
                         6.1.4.3 Product benchmarking
                     6.1.5 BioCryst Pharmaceuticals, Inc
                         6.1.5.1 Company overview
                         6.1.5.2 Financial performance
                         6.1.5.3 Product benchmarking
                         6.1.5.4 Strategic initiatives
                     6.1.6 Boehringer Ingelheim GmbH
                         6.1.6.1 Company overview
                         6.1.6.2 Financial performance
                         6.1.6.3 Product benchmarking
                         6.1.6.4 Strategic initiatives
                     6.1.7 Novartis International AG
                         6.1.7.1 Company overview
                         6.1.7.2 Financial performance
                         6.1.7.1 Product benchmarking
                         6.1.7.4 Strategic initiatives
                     6.1.8 Merck & Co., Inc.
                         6.1.8.1 Company overview
                         6.1.8.2 Financial performance
                         6.1.8.1 Product benchmarking
                         6.1.8.4 Strategic initiatives

List of Tables

TABLE 1 Number of people living with HIV and % of HIV population on ART
TABLE 2 HBV and HCV epidemic in WHO regions in 2015
TABLE 3 HIV therapeutics market estimates & forecasts, by drug type, 2014 - 2025 (USD Million)
TABLE 4 TB therapeutics market estimates & forecasts, by drug type, 2014 - 2025 (USD Million)
TABLE 5 Malaria therapeutics market estimates & forecasts, by drug type, 2014 - 2025 (USD Million)
TABLE 6 Influenza therapeutics market estimates & forecasts, by drug type, 2014 - 2025 (USD Million)
TABLE 7 North America top six infectious disease therapeutics market estimates & forecasts, by type, 2014 - 2025 (USD Million)
TABLE 8 U.S. top six infectious disease therapeutics market estimates & forecasts, by disease type, 2014 - 2025 (USD Million)
TABLE 9 Canada top six infectious disease therapeutics market estimates & forecasts, by disease type, 2014 - 2025 (USD Million)
TABLE 10 Europe top six infectious disease therapeutics market estimates & forecasts, by disease type, 2014 - 2025 (USD Million)
TABLE 11 UK top six infectious disease therapeutics market estimates & forecasts, by disease type, 2014 - 2025 (USD Million)
TABLE 12 Germany top six infectious disease therapeutics market estimates & forecasts, by disease type, 2014 - 2025 (USD Million)
TABLE 13 Asia Pacific top six infectious disease therapeutics market estimates & forecasts, by disease type, 2014 - 2025 (USD Million)
TABLE 14 Japan top six infectious disease therapeutics market estimates & forecasts, by disease type, 2014 - 2025 (USD Million)
TABLE 15 China top six infectious disease therapeutics market estimates & forecasts, by disease type, 2014 - 2025 (USD Million)
TABLE 16 Latin America top six infectious disease therapeutics market estimates & forecasts, by disease type, 2014 - 2025 (USD Million)
TABLE 17 Brazil top six infectious disease therapeutics market estimates & forecasts, by disease type, 2014 - 2025 (USD Million)
TABLE 18 Mexico top six infectious disease therapeutics market estimates & forecasts, by disease type, 2014 - 2025 (USD Million)
TABLE 19 MEA top six infectious disease therapeutics market estimates & forecasts, by disease type, 2014 - 2025 (USD Million)
TABLE 20 South Africa top six infectious disease therapeutics market estimates & forecasts, by disease type, 2014 - 2025 (USD Million)